Safety, Activity Seen with Frontline Zanidatamab Plus Chemo ± Bevacizumab in HER2+ mCRC
September 14th 2024Zanidatamab combined with chemotherapy demonstrated promising antitumor activity and safety in the first-line treatment of HER2-positive mCRC, with a high response rate and manageable adverse effects.
In CLL/SLL, Zanubrutinib Linked to Lower Switch Rates vs Other BTK Inhibitors
September 12th 2024Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.